The Sahlgrenska University Hospital is a hospital network associated with the Sahlgrenska Academy at the University of Gothenburg in Gothenburg, Sweden. With 17,000 employees the hospital is the largest hospital in Sweden by a considerable margin, and the second largest hospital in Europe.

There are 2,000 beds in Sahlgrenska University Hospital, Dept of Oncology.

During the past decade, Sahlgrenska University Hospital, Dept of Oncology conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Sahlgrenska University Hospital, Dept of Oncology" #1 collaborator was "Advanced Accelerator Applications" with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator, "Karolinska University Hospital" with 1 trials as a collaborator, "Lund University Hospital" with 1 trials as a collaborator and "Novartis" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Sahlgrenska University Hospital, Dept of Oncology" are "Neuroendocrine Tumors" (2 trials), "Clinical Trial, Phase I" (1 trials), "Gastrointestinal Stromal Tumors" (1 trials), "Glioblastoma" (1 trials) and "Glioma" (1 trials). Many other conditions were trialed in "Sahlgrenska University Hospital, Dept of Oncology" in a lesser frequency.

Most popular intervention types in "Sahlgrenska University Hospital, Dept of Oncology" are "Drug" (4 trials), "Combination Product" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "177Lu-DOTA-TATE + olaparib" (1 trials), "211-astatine MX35 F(ab')2" (1 trials), "Alkylating Agents" (1 trials), "Avelumab (MSB0010718C)" (1 trials) and "Axitinib (AG-013736)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sahlgrenska University Hospital, Dept of Oncology" are 5 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Sahlgrenska University Hospital, Dept of Oncology". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Sahlgrenska University Hospital, Dept of Oncology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Sahlgrenska University Hospital, Dept of Oncology, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".